Clinical Manifestations and Disease Burden of Primary Mitochondrial Myopathies (PMM): Results from a Patient Journey Analysis Shows Substantial Healthcare Resource Utilization

Sirimanne et al., Academy of Managed Care Pharmacy Nexus Annual Meeting; October 16-19, 2023

Predictive Physiologically Based Pharmacokinetic (PBPK) Model Suggests Minimal Drug-Drug Interaction (DDI) Between PPARδ Agonist Mavodelpar (REN001) & Rosuvastatin

Emery et al., ACCP Annual Meeting, Bellevue, WA

A Phase 1 Randomized, Placebo-Controlled, Parallel Study of the Novel Peroxisome Proliferator-Activated Receptor δ Agonist REN001 in Healthy Volunteers during and After Limb Immobilization

Davies et al., Journal of Clinical Trials 2022

Treatment with REN001, a Novel PPARδ Agonist, Preserves Muscle Strength and Promotes Recovery of Muscle Atrophy After Prolonged Leg Immobilization

Davies et al., International Congress on Neuromuscular Diseases, 2022

An open-label study to evaluate the safety and tolerability of 12 weeks treatment with oral REN001 in patients with primary mitochondrial myopathy (PMM), with an optional extension of treatment

Gorman et al.,Wellcome Trust UK Mitochondrial Medicine, 2021

Development of a Patient-Reported Outcome Questionnaire for Patients with Fatty Acid Oxidation Disorders

Mathias et al., INFORM, 2019

Peroxisome Proliferator-Activated Receptor δ Agonist, HPP593, Prevents Renal Necrosis under Chronic Ischemia

Fedorova et al., PLOS ONE 2013